TY - JOUR
T1 - Uptake Kinetics Of Liposomal Formulations of Differing Charge Influences Development of in Vivo Dendritic Cell Immunotherapy
AU - Nagy, Noémi Anna
AU - Castenmiller, Charlotte
AU - Vigario, Fernando Lozano
AU - Sparrius, Rinske
AU - van Capel, Toni M. M.
AU - de Haas, Aram M.
AU - van Kooyk, Yvette
AU - van Ree, Ronald
AU - Tas, Sander W.
AU - Geijtenbeek, Teunis B. H.
AU - Jiskoot, Wim
AU - Slütter, Bram
AU - de Jong, Esther C.
N1 - Funding Information:
The authors thank Esther Taanman-Kueter, Charlotte van Rooijen, Daisy Picavet-Havik and Gabrielle Krebbers for technical assistance with experiments, Kim Brandwijk-Paarlberg for valuable input on imaging flow cytometry analysis, Joke Bouwstra and Alexander Kros for intriguing liposomal discussions, members of the DC4Balance consortium, as well as Health Holland and ?Samenwerkende Gezondheidsfonden? (SGF) for funding. This work was supported by LSH-TKI project DC4Balance LSHM18056-SGF.
Funding Information:
The authors thank Esther Taanman-Kueter, Charlotte van Rooijen, Daisy Picavet-Havik and Gabrielle Krebbers for technical assistance with experiments, Kim Brandwijk-Paarlberg for valuable input on imaging flow cytometry analysis, Joke Bouwstra and Alexander Kros for intriguing liposomal discussions, members of the DC4Balance consortium, as well as Health Holland and “Samenwerkende Gezondheidsfonden” (SGF) for funding. This work was supported by LSH-TKI project DC4Balance LSHM18056-SGF.
Publisher Copyright:
© 2022 The Authors
PY - 2022/4
Y1 - 2022/4
N2 - Dendritic cells (DCs) control adaptive immunity and are therefore attractive for in vivo targeting to either induce immune activation or tolerance, depending on disease. Liposomes, nanoparticles comprised of a lipid bi-layer, provide a nanoplatform for loading disease-relevant antigen, adjuvant and DC-targeting molecules simultaneously. However, it is yet not fully understood how liposomal formulations affect uptake by DCs and DC function. Here, we examined monocyte-derived DC (moDC) and skin DC uptake of six different liposomal formulations, together with their DC-modulating effect. Contrary to literature, we show using imaging flow cytometry that anionic or neutral liposomes are taken up more efficiently than cationic liposomes by moDCs, or by skin DCs after intradermal injection. None of the formulations yielded significant modulation of DC function as determined by the upregulation of maturation markers and cytokine production. These results suggest that anionic liposomes would be more suitable as vaccine carriers for a dermal application.
AB - Dendritic cells (DCs) control adaptive immunity and are therefore attractive for in vivo targeting to either induce immune activation or tolerance, depending on disease. Liposomes, nanoparticles comprised of a lipid bi-layer, provide a nanoplatform for loading disease-relevant antigen, adjuvant and DC-targeting molecules simultaneously. However, it is yet not fully understood how liposomal formulations affect uptake by DCs and DC function. Here, we examined monocyte-derived DC (moDC) and skin DC uptake of six different liposomal formulations, together with their DC-modulating effect. Contrary to literature, we show using imaging flow cytometry that anionic or neutral liposomes are taken up more efficiently than cationic liposomes by moDCs, or by skin DCs after intradermal injection. None of the formulations yielded significant modulation of DC function as determined by the upregulation of maturation markers and cytokine production. These results suggest that anionic liposomes would be more suitable as vaccine carriers for a dermal application.
KW - Cationic lipid(s)
KW - Cell culture
KW - Drug delivery system(s)
KW - Immunogenicity
KW - Immunology
KW - Immunotherapy
KW - Lipid nanoparticle(s)
KW - Liposome(s)
KW - Nanomedicine
KW - Skin
UR - http://www.scopus.com/inward/record.url?scp=85124391037&partnerID=8YFLogxK
U2 - 10.1016/j.xphs.2022.01.022
DO - 10.1016/j.xphs.2022.01.022
M3 - Article
C2 - 35114209
SN - 0928-0987
VL - 111
SP - 1081
EP - 1091
JO - European Journal of Pharmaceutical Sciences
JF - European Journal of Pharmaceutical Sciences
IS - 4
ER -